ARWR
ArrowheadCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
+
Peers tracked
9
U.S. public peers
Grade Position
In line
vs peer average
ARWR vs peer average
61/100
ARWR vs. peer average (C vs. D)
Grade spread
C 6 · F 3
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
IONS is the first available peer comparator.
Ionis is the most direct operating comparator for Arrowhead's near-term commercial debate because the packet's earnings context says more than 10% of REDEMPLO prescriptions were switch patients from a competing APOC3 inhibitor; payer access, switching, persistence, and paid-claim conversion are therefore the clearest peer benchmarks [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-08].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ARWR
Arrowhead
IONS
Ionis
Grade
C
C
Momentum
60
4
Value
49
41
Sentiment
42
100
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Mixed
Grade position vs IONS
ARWR / IONS
Grade Position
In line
ARWR vs. peer average (C vs. D)
61/100
Momentum
60
ARWRValue
49
ARWRSentiment
42
IONSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ARWR
IONS is the first peer returned for this comparison set.